Phase I pharmacologic study of oral topotecan and intravenous cisplatin : Sequence-dependent hematologic side effects
In: Journal of clinical oncology, Jg. 18 (2000), Heft 10, S. 2104-2115
Online
academicJournal
- print, 52 ref
Zugriff:
Purpose: In in vitro studies, synergism and sequence-dependent effects were reported for the combination of topotecan and cisplatin. Recently, an oral formulation of topotecan became available. This phase I study was performed to assess the feasibility of the combination of oral topotecan and cisplatin, the pharmacokinetic interaction, and sequence-dependent effects. Patients and Methods: Topotecan was administered orally (PO) daily for 5 days in escalating doses and cisplatin was given intravenously (IV) at a fixed dose of 75 mg/m2 either before topotecan administration on day 1 (sequence CT) or after topotecan administration on day 5 (sequence TC) once every 3 weeks. Patients were treated in a randomized cross-over design. Results: Forty-nine patients were entered onto the study; one patient was not eligible. Sequence CT induced significantly more severe myelosuppression than did sequence TC, and the maximum-tolerated dosage of topotecan in sequence CT was 1.25 mg/m2/d x 5. In sequence TC, the maximum-tolerated dosage of topotecan was 2.0 mg/m2/d x 5. Dose-limiting toxicity consisted of myelosuppression and diarrhea. Pharmacokinetics of topotecan and cisplatin were linear over the dose range studied; no sequence-dependent effects were observed. In addition, topotecan did not influence the protein binding of cisplatin or the platinum-DNA adduct formation in peripheral leukocytes in either sequence. Conclusion: The recommended dosages for phase II studies involving patients like the patients in our study are topotecan 1.25 mg/m2/d PO x 5 preceded by cisplatin 75 mg/m2 IV day 1 once every 3 weeks, and topotecan 2.0 mg/m2/d PO followed by cisplatin 75 mg/m2 IV day 5. No pharmacokinetic interaction could be discerned in our study. The antitumor efficacy of both schedules should be evaluated in a randomized phase II study.
Titel: |
Phase I pharmacologic study of oral topotecan and intravenous cisplatin : Sequence-dependent hematologic side effects
|
---|---|
Autor/in / Beteiligte Person: | DE JONGE, M. J. A ; LOOS, W. J ; HEARN, S ; ROSS, G ; VERWEIJ, J ; GELDERBLOM, H ; PLANTING, A. S. T ; VAN DER BURG, M. E. L ; SPARREBOOM, A ; BROUWER, E ; VAN BEURDEN, V ; MANTEL, M. A ; DOYLE, E |
Link: | |
Zeitschrift: | Journal of clinical oncology, Jg. 18 (2000), Heft 10, S. 2104-2115 |
Veröffentlichung: | Baltimore, MD: Lippincott Williams & Wilkins, 2000 |
Medientyp: | academicJournal |
Umfang: | print, 52 ref |
ISSN: | 0732-183X (print) |
Schlagwort: |
|
Sonstiges: |
|